USA's DHHS to investigate sudden hike in generic drug prices

16 April 2015

At the urging of US Senator Bernie Sanders and Representative Elijah Cummings, the Department of Health and Human Services’ Inspector General has agreed to investigate how sudden price hikes by generic drug makers are driving up the cost of taxpayer-supported health care.

It is unacceptable that Americans pay, by far, the highest prices in the world for prescription drugs. Generic drugs were meant to help make medications affordable for millions of Americans who rely on prescriptions to manage their health needs. We’ve got to get to the bottom of these enormous price increases,” said Sen Sanders (Independent, Vermont).

“It is outrageous that skyrocketing prices of generic drugs are preventing patients from getting the medications they need,” said Rep Cummings (Democrat, Maryland), adding: “I am very pleased that the inspector general has agreed to investigate how these price hikes are driving up costs to taxpayers."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics